Quantitation of cytochrome P450 mRNAs in patients with suspected liver diseases as assessed by reverse transcriptase–polymerase chain reaction

Gonzalez, 1990, Molecular genetics of the P-450 superfamily, Pharmacol Ther, 45, 1, 10.1016/0163-7258(90)90006-N Nelson, 1993, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature, DNA Cell Biol, 12, 1, 10.1089/dna.1993.12.1 Watkins, 1985, Identification of an inducible form of cytochrome P450 in human liver, Proc Natl Acad Sci USA, 82, 6310, 10.1073/pnas.82.18.6310 Guengerich, 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes, Chem Res Toxicol, 4, 391, 10.1021/tx00022a001 Murray, 1992, P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease, Clin Pharmacokinet, 23, 132, 10.2165/00003088-199223020-00005 Mahgoub, 1977, Polymorphic hydroxylation of debrisoquine in man, Lancet, 2, 584, 10.1016/S0140-6736(77)91430-1 de Morais, 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J Biol Chem, 269, 15419, 10.1016/S0021-9258(17)40694-6 Guengerich, 1989, Polymorphism of cytochrome P-450 in humans, Trends Pharmacol Sci, 10, 107, 10.1016/0165-6147(89)90207-1 Tucker, 1994, Clinical implications of genetic polymorphism in drug metabolism, J Pharm Pharmacol, 46, 417 Gough, 1990, Identification of the primary gene defect at the cytochrome P450 CYP2D locus, Nature, 347, 773, 10.1038/347773a0 Gonzalez, 1994, Pharmacogenetic phenotyping and genotyping: present status and future potential, Clin Pharmacokinet, 26, 59, 10.2165/00003088-199426010-00005 Finnström, 1995, Varying cytochrome P450 specific mRNA levels in liver disease as assessed in needle biopsies Vanden Heuvel, 1993, Construction of recombinant RNA templates for use as internal standard in quantitative RT-PCR, Biotechniques, 14, 395 Gilliland, 1990, Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain raction, Proc Natl Acad Sci USA, 87, 2725, 10.1073/pnas.87.7.2725 Vanden Heuvel, 1993, CYP1A1 mRNA levels as human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes, Carcinogenesis, 14, 2003, 10.1093/carcin/14.10.2003 Durnam, 1983, A practical approach for quantitating specific mRNAs by solution hybridization, Anal Biochem, 131, 385, 10.1016/0003-2697(83)90188-4 Melton, 1984, Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter, Nucleic Acids Res, 12, 7035, 10.1093/nar/12.18.7035 Rane, 1994, Opiate-specific effects on mRNA and catalytic activity of a hepatic cytochrome P450 isozyme, Regul Pept, 1, 273, 10.1016/0167-0115(94)90345-X Andersen, 1998, Quantification of multiple human cytochrome P450 mRNA molecules using competititve reverse transcriptase-PCR, DNA Cell Biol, 17, 231, 10.1089/dna.1998.17.231 Schweikl, 1993, Expression of CYP1A1 and CYP1A2 genes in human liver, Pharmacogenetics, 3, 239, 10.1097/00008571-199310000-00003 George, 1995, Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with chirrosis, Biochem Pharmacol, 49, 873, 10.1016/0006-2952(94)00515-N Ingelman-Sundberg, 1993, Ethanol-inducible CYP2E1: toxicological importance and regulation by nutrients, 149 Hakkola, 1994, Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver, Biochem Pharmacol, 48, 59, 10.1016/0006-2952(94)90223-2